ERGOMED

News

London, UK, September 18, 2017

Unaudited Interim results for the six months ended 30 June 2017

Strong first half financial performance – net service revenues up 53% and gross profit up 42%

Haemostatix programmes significantly advanced, PeproStat™ Phase IIb study ahead of schedule


London, UK – 18 September 2017: Ergomed plc, (“Ergomed”, the “Company”, AIM: ERGO) a company dedicated to the provision of specialised services to the pharmaceutical industry and the development…


London, UK, 24 July 2017

Ergomed completes Phase IIb study recruitment six months ahead of schedule for its innovative coagulant PeproStat

– Top line results expected in Q4 2017, six months earlier than anticipated.
– Faster than expected recruitment reflects Ergomed’s strong CRO capabilities.

London, UK – 24 July 2017: Ergomed plc (LSE: ERGO) (‘Ergomed’ or the ‘Company’), a specialised pharmaceutical services and drug development company, today announces that recruitment has been completed ahead of schedule in…


London, UK, 21 June 2017

PeproStat Phase IIb study passes recruitment mid-point ahead of schedule – Top line results brought forward to Q4 2017

London, UK – 21 June 2017: Ergomed plc (LSE: ERGO) (‘Ergomed’ or the ‘Company’), a company dedicated to the provision of specialised services to the pharmaceutical industry and the development of new drugs, today announces that its Phase IIb proof-of-concept study for PeproStat, Ergomed’s highly innovative new coagulant, or ‘haemostat’, for intraoperative…


London, UK, 16 June 2017

Results of 2017 Annual General Meeting

London, UK –16 June 2017: Ergomed plc (LSE: ERGO) (‘Ergomed’ or ‘the Company’), a company dedicated to the provision of specialised services to the pharmaceutical industry and the development of new drugs, today announces that all resolutions put to shareholders were duly passed at its Annual General Meeting held earlier today.


London, UK, 16 June 2017

Ergomed strengthens executive team with appointment of Dr Dan Weng as CEO

– Founder Dr Miroslav Reljanovic to become Executive Vice-Chairman

London, UK – 16 June 2017: Ergomed plc (LSE: ERGO) (‘Ergomed’ or ‘the Company’), a company dedicated to the provision of specialised services to the pharmaceutical industry and the development of new drugs, today announces the strengthening of its executive team with…


Page 3 of 1912345...10...Last »
Translate »